<DOC>
	<DOCNO>NCT01384253</DOCNO>
	<brief_summary>Monoclonal antibody transport deliver radioactive element capable release sufficient amount energy destroy tumor cell . In clinical trial , study alpha particle radio immunotherapy use lead-212 ( ²¹²Pb ) , isotope short path length target malignant cell trastuzumab antibody , potential treatment metastatic disease . This Phase I trial design determine toxicity profile ²¹²Pb-TCMC-Trastuzumab , dose-limiting toxicity , anti-tumor effect patient HER-2 positive intraperitoneal cancer .</brief_summary>
	<brief_title>Safety Study ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>1 . At least 19 year age . 2 . Life expectancy great three month . 3 . Female subject childbearing potential must negative serum pregnancy test . 4 . If surgically sterile , male female patient childbearing potential must use double barrier contraception ( e.g. , hormonal ; intrauterine device ; barrier ) . 5 . Patients HER2 express tumor ( e.g. , ovarian , pancreatic , colon , gastric , endometrial , breast ) measurable nonmeasurable disease standard therapy available . 6 . HER2 amplification fluorescent situ hybridization HER2 score least least 1+ Immunohistochemistry 10 % cell . Alternatively , HER2 serum level great 15ng/mL ELISA . 7 . Disease must predominantly intraabdominal include document peritoneal stud positive peritoneal washing . 8 . Able willing sign inform consent form . 1 . ECOG performance status great 3 . 2 . Any serious active disease comorbid condition , opinion investigator , may interfere safety compliance study . 3 . Poor bone marrow reserve define absolute neutrophil count le 1.5 x 10³/cmm platelet less 100 x 10³/cmm within two week prior initiation treatment . 4 . Liver metastasis . 5 . Poor organ function define one following : Total bilirubin great 1.5 upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) great 2.5 ULN great 5 ULN case document liver metastasis Serum creatinine great ULN , except calculate creatinine clearance great 60 mL/min Urine Protein/Creatinine Ratio great 1 morning spot urinalysis proteinuria great 500 mg/24 h 6 . Breastfeeding woman . 7 . No resolution specific toxicity ( exclude alopecia ) relate prior anticancer therapy Grade 2 accord National Cancer Institute common terminology criterion adverse event ( NCI CTCAE ) v.4.03 nausea vomit Grade 3 uncontrolled antiemetic . 8 . Wash period less three week previous antitumor therapy investigational treatment ( less six week case prior nitrosourea mitomycin C treatment ) schedule date administration . 9 . Wash period le one week last palliative dose radiotherapy . 10 . Any severe underlying medical condition could impair ability participate study interpretation result related investigational product : Patients abnormal cardiac function define leave ventricular ejection fraction ( LVEF ) less 50 % echocardiogram ( ECHO ) multi gate acquisition ( MUGA ) scan Patients previous history acute cardiac failure 11 . Clinical symptom bowel obstruction , evidence rectosigmoid bowel involvement exam , transmural bowel wall involvement compute tomography ( CT ) magnetic resonance imaging ( MRI ) . 12 . Prior whole abdomen radiation therapy exceed 4Gy , intraperitoneal radionuclide therapy , bone marrow transplant , stem cell transplant . 13 . History Human Immunodeficiency Virus ( HIV ) antibody enzymelinked immunosorbent assay ( ELISA ) negative Western blot ( ELISA positive ) hepatitis B surface antigen ( HBsAg ) potential add toxicity radiolabeled antibody among patient infected virus . 14 . Detectable human antihuman antibody ( HAHA ) history monoclonal antibody exposure . 15 . Iodine allergy patient unwilling accept radiation thyroid uptake radionuclide without block . 16 . Allergy furosemide patient unwilling accept radiation risk without agent alternative feasible . 17 . History cumulative anthracycline therapy exceed 200 mg/m² doxorubicin comparable low dose anthracyclines .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>HER2+</keyword>
	<keyword>HER-2 positive</keyword>
	<keyword>intraperitoneal</keyword>
	<keyword>intra-abdominal</keyword>
	<keyword>Lead 212</keyword>
	<keyword>Radio Immunotherapy</keyword>
	<keyword>Alpha particle</keyword>
	<keyword>Antibodies</keyword>
	<keyword>Immunoglobulins</keyword>
	<keyword>Antibodies , Monoclonal</keyword>
	<keyword>Immunologic Factors</keyword>
	<keyword>Physiological Effects Drugs</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>RIT</keyword>
</DOC>